CN101730698B - 用于治疗丙型肝炎的化合物 - Google Patents
用于治疗丙型肝炎的化合物 Download PDFInfo
- Publication number
- CN101730698B CN101730698B CN2008800163317A CN200880016331A CN101730698B CN 101730698 B CN101730698 B CN 101730698B CN 2008800163317 A CN2008800163317 A CN 2008800163317A CN 200880016331 A CN200880016331 A CN 200880016331A CN 101730698 B CN101730698 B CN 101730698B
- Authority
- CN
- China
- Prior art keywords
- hcv
- alkyl
- cyclohexyl
- compound
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)*(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(N(CC(C3)CC4)C3CC4(C)O)=O)c2c1)=O)=O Chemical compound CC(C)*(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(N(CC(C3)CC4)C3CC4(C)O)=O)c2c1)=O)=O 0.000 description 3
- VRFSIKVVIYAPGH-UHFFFAOYSA-N CC(C)NC(CC1CC2)CC2N1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(N(C)C)(=O)=O)=O)=O Chemical compound CC(C)NC(CC1CC2)CC2N1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(N(C)C)(=O)=O)=O)=O VRFSIKVVIYAPGH-UHFFFAOYSA-N 0.000 description 1
- RRUMWCRPJBNVJD-UHFFFAOYSA-N CC(C)S(NC(c1cc(N(CC2(C3C2)C(N(C(CC2)C4)C2CC4N(C)Cc2ccccc2)=O)C(C2C4CCCCC4)c(cc4)c3cc4OC)c2cc1)=O)(=O)=O Chemical compound CC(C)S(NC(c1cc(N(CC2(C3C2)C(N(C(CC2)C4)C2CC4N(C)Cc2ccccc2)=O)C(C2C4CCCCC4)c(cc4)c3cc4OC)c2cc1)=O)(=O)=O RRUMWCRPJBNVJD-UHFFFAOYSA-N 0.000 description 1
- ZLDPABQYWWXCSH-BUDUUTIJSA-N CC(CC1CC2)(CC2N1C([C@]1(C2)[C@@H]2c(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(NS(N(C)C)(=O)=O)=O)c3)c3[n]2C1)=O)O Chemical compound CC(CC1CC2)(CC2N1C([C@]1(C2)[C@@H]2c(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(NS(N(C)C)(=O)=O)=O)c3)c3[n]2C1)=O)O ZLDPABQYWWXCSH-BUDUUTIJSA-N 0.000 description 1
- LYAJVNXCVCHYDF-UHFFFAOYSA-N CCC(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(N(C(CC3)C4)C3CC4NC)=O)c2c1)=O)(=O)=O Chemical compound CCC(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(N(C(CC3)C4)C3CC4NC)=O)c2c1)=O)(=O)=O LYAJVNXCVCHYDF-UHFFFAOYSA-N 0.000 description 1
- IWYAULVVEFYJRL-UHFFFAOYSA-N CCC(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O Chemical compound CCC(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O IWYAULVVEFYJRL-UHFFFAOYSA-N 0.000 description 1
- HGSGPIFFCRTHDW-UHFFFAOYSA-N CCN(CC)S(NC(c(cc1)cc2c1c(C)c(-c(cc1)c(C3C4)cc1OC)[n]2CC34C(O)=O)=O)(=O)=O Chemical compound CCN(CC)S(NC(c(cc1)cc2c1c(C)c(-c(cc1)c(C3C4)cc1OC)[n]2CC34C(O)=O)=O)(=O)=O HGSGPIFFCRTHDW-UHFFFAOYSA-N 0.000 description 1
- HEGHOFIZWVHSNQ-UHFFFAOYSA-N CCS(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O Chemical compound CCS(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O HEGHOFIZWVHSNQ-UHFFFAOYSA-N 0.000 description 1
- FWWVEERRQHXMLD-UHFFFAOYSA-N CN(C)CCN(Cc1ccccc1)C(CC1CC2)CC2N1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NCS(C)=O)=O)=O Chemical compound CN(C)CCN(Cc1ccccc1)C(CC1CC2)CC2N1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NCS(C)=O)=O)=O FWWVEERRQHXMLD-UHFFFAOYSA-N 0.000 description 1
- DJMPPRZIHRHKIL-UHFFFAOYSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O DJMPPRZIHRHKIL-UHFFFAOYSA-N 0.000 description 1
- LEDMIRJVLINYEY-UHFFFAOYSA-N COC(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(CC(F)(F)F)(=O)=O)=O)=O Chemical compound COC(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(CC(F)(F)F)(=O)=O)=O)=O LEDMIRJVLINYEY-UHFFFAOYSA-N 0.000 description 1
- UQPZMXYRGLMMEE-UHFFFAOYSA-N COc(cc1)cc(C(C2)C2(C[n]2c3c4)C(N5C6COCC5CCC6)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CCCCC1)(=O)=O)=O Chemical compound COc(cc1)cc(C(C2)C2(C[n]2c3c4)C(N5C6COCC5CCC6)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CCCCC1)(=O)=O)=O UQPZMXYRGLMMEE-UHFFFAOYSA-N 0.000 description 1
- ZVUVBRNZBOZLBU-UHFFFAOYSA-N OC(c1ccc(c(C2CCCCC2)c([nH]2)Br)c2c1)=O Chemical compound OC(c1ccc(c(C2CCCCC2)c([nH]2)Br)c2c1)=O ZVUVBRNZBOZLBU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89488507P | 2007-03-14 | 2007-03-14 | |
| US60/894,885 | 2007-03-14 | ||
| US98947307P | 2007-11-21 | 2007-11-21 | |
| US60/989,473 | 2007-11-21 | ||
| US12/045,874 US7541353B2 (en) | 2007-03-14 | 2008-03-11 | Compounds for the treatment of hepatitis C |
| US12/045,874 | 2008-03-11 | ||
| PCT/US2008/056778 WO2008112848A1 (en) | 2007-03-14 | 2008-03-13 | Compounds for the treatment of hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101730698A CN101730698A (zh) | 2010-06-09 |
| CN101730698B true CN101730698B (zh) | 2012-09-05 |
Family
ID=39760022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800163317A Expired - Fee Related CN101730698B (zh) | 2007-03-14 | 2008-03-13 | 用于治疗丙型肝炎的化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7541353B2 (enExample) |
| EP (1) | EP2118108B1 (enExample) |
| JP (1) | JP5301473B2 (enExample) |
| CN (1) | CN101730698B (enExample) |
| ES (1) | ES2397740T3 (enExample) |
| WO (1) | WO2008112848A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| PL2209789T3 (pl) * | 2007-11-20 | 2012-04-30 | Bristol Myers Squibb Co | Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8138171B2 (en) * | 2008-03-27 | 2012-03-20 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors |
| EP2280978B1 (en) * | 2008-03-27 | 2013-04-24 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
| US8178523B2 (en) * | 2008-03-27 | 2012-05-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US8445497B2 (en) * | 2010-06-30 | 2013-05-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005013922D1 (de) | 2004-02-24 | 2009-05-28 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2005298403A1 (en) | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN101490054B (zh) | 2006-05-25 | 2012-05-16 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
-
2008
- 2008-03-11 US US12/045,874 patent/US7541353B2/en active Active
- 2008-03-13 JP JP2009553763A patent/JP5301473B2/ja not_active Expired - Fee Related
- 2008-03-13 WO PCT/US2008/056778 patent/WO2008112848A1/en not_active Ceased
- 2008-03-13 CN CN2008800163317A patent/CN101730698B/zh not_active Expired - Fee Related
- 2008-03-13 ES ES08732082T patent/ES2397740T3/es active Active
- 2008-03-13 EP EP08732082A patent/EP2118108B1/en not_active Not-in-force
Non-Patent Citations (1)
| Title |
|---|
| 程会云.手性药物的对映异构体在生物体中生理活性差异.《北方药学》.2005,第2卷(第5期),第5-6页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2118108B1 (en) | 2012-11-14 |
| US7541353B2 (en) | 2009-06-02 |
| JP5301473B2 (ja) | 2013-09-25 |
| JP2010521482A (ja) | 2010-06-24 |
| ES2397740T3 (es) | 2013-03-11 |
| EP2118108A1 (en) | 2009-11-18 |
| CN101730698A (zh) | 2010-06-09 |
| US20080226591A1 (en) | 2008-09-18 |
| WO2008112848A1 (en) | 2008-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101730698B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101918410B (zh) | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| CN101679441B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN101679442B (zh) | 用于治疗丙型肝炎的化合物 | |
| EP2024375B1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| US7485633B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| US7521443B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| EP2118109B1 (en) | Compounds for the treatment of hepatitis c | |
| CN101631790B (zh) | 用于治疗丙型肝炎的化合物 | |
| US8129367B2 (en) | Compounds for the treatment of Hepatitis C | |
| CN101918412B (zh) | 用于治疗丙型肝炎的稠合有环丙基的吲哚并苯并氮杂*衍生物 | |
| JP2010521483A (ja) | シクロプロピル縮合インドロベンゾアゼピンｈｃｖインヒビター | |
| CN101646674B (zh) | 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物 | |
| CN101443336B (zh) | 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂 | |
| HK1122814B (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120905 Termination date: 20150313 |
|
| EXPY | Termination of patent right or utility model |